Reports Q1 revenue $11.12B, consensus $11.78B. Commenting on the results, Vas Narasimhan, CEO of Novartis, said: “Novartis is off to a strong start in 2019 with the Mayzent launch, successful Alcon spin-off, and strong operational execution leading us to revise 2019 profit guidance upwards. We enter an exciting period with expected launches of Zolgensma, BYL719 and brolucizumab and multiple late stage readouts. With our strong pipeline, focus on productivity, and commitment to cultural transformation, we are well positioned for growth in 2019 and the future.”
https://thefly.com/landingPageNews.php?id=2896187
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.